peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Bulletin from the Annual General Meeting of Hansa Medical AB (publ) 2011

13 May 2011, 08:00
Regulatory information
The Hansa Medical AB (publ) Annual General Meeting, was held on Thursday May 12 in Lund.

The complete bulletin is available in Swedish only, and available below or at

For further information, please contact:
Emanuel Björne, CEO
Mobile: +46707-17 54 77

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.